Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fogelman

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Cancer Chemotherapy and Pharmacology|August 19, 2011
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysisHassan K Dakik, Daniel J Moskovic, Peter J Carlson, et al.
Investigational New Drugs|May 7, 2013
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancerMohamed A Khalil, Wei Qiao, Peter Carlson, et al.
Cancer|May 16, 2015
Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancerManasi S Shah, David R Fogelman, Kanwal Pratap Singh Raghav, et al.
Journal of Hematology & Oncology|May 31, 2018
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinomaReham Abdel-Wahab, Gauri R Varadhachary, Priya R Bhosale, et al.
Journal of Lipid Research|March 12, 2016
Tg6F ameliorates the increase in oxidized phospholipids in the jejunum of mice fed unsaturated LysoPC or WDArnab Chattopadhyay, Mohamad Navab, Greg Hough, et al.
The Lancet. Oncology|May 10, 2015
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 studyAlexandria T Phan, Daniel M Halperin, Jennifer A Chan, et al.
Clinical Colorectal Cancer|October 14, 2009
Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injuryJulian H Slade, Mona L Alattar, David R Fogelman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 24, 2017
A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patientsDavid R Fogelman, J Morris, L Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic CancerJennifer B Goldstein, Li Zhao, Xuemei Wang, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 18, 2014
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?David R Fogelman, Holly Holmes, Khalil Mohammed, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Cancer Chemotherapy and Pharmacology|August 19, 2011
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysisHassan K Dakik, Daniel J Moskovic, Peter J Carlson, et al.
Investigational New Drugs|May 7, 2013
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancerMohamed A Khalil, Wei Qiao, Peter Carlson, et al.
Cancer|May 16, 2015
Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancerManasi S Shah, David R Fogelman, Kanwal Pratap Singh Raghav, et al.
Journal of Hematology & Oncology|May 31, 2018
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinomaReham Abdel-Wahab, Gauri R Varadhachary, Priya R Bhosale, et al.
Journal of Lipid Research|March 12, 2016
Tg6F ameliorates the increase in oxidized phospholipids in the jejunum of mice fed unsaturated LysoPC or WDArnab Chattopadhyay, Mohamad Navab, Greg Hough, et al.
The Lancet. Oncology|May 10, 2015
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 studyAlexandria T Phan, Daniel M Halperin, Jennifer A Chan, et al.
Clinical Colorectal Cancer|October 14, 2009
Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injuryJulian H Slade, Mona L Alattar, David R Fogelman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 24, 2017
A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patientsDavid R Fogelman, J Morris, L Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic CancerJennifer B Goldstein, Li Zhao, Xuemei Wang, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 18, 2014
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?David R Fogelman, Holly Holmes, Khalil Mohammed, et al.
Pageof 6